191 related articles for article (PubMed ID: 24285769)
1. Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
Shah S; Coakley C; Hough A; Parra D
Ann Pharmacother; 2013 Nov; 47(11):1562-8. PubMed ID: 24285769
[TBL] [Abstract][Full Text] [Related]
2. Plasma renin activity testing to guide triple antirenin system drug therapy in a patient with difficult-to-treat hypertension.
Shah S; Coakley C; Hough A; Parra D
Ann Pharmacother; 2014 Feb; 48(2):279-85. PubMed ID: 24259655
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
Stanton AV; Dicker P; O'Brien ET
Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
[TBL] [Abstract][Full Text] [Related]
4. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
[TBL] [Abstract][Full Text] [Related]
7. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension.
Flack JM; Yadao AM; Purkayastha D; Samuel R; White WB
J Am Soc Hypertens; 2012; 6(2):142-51. PubMed ID: 22321963
[TBL] [Abstract][Full Text] [Related]
11. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Chrysant SG
Postgrad Med; 2011 Nov; 123(6):21-31. PubMed ID: 22104451
[TBL] [Abstract][Full Text] [Related]
12. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.
Sealey JE; Laragh JH
Am J Hypertens; 2009 Jan; 22(1):112-21. PubMed ID: 18802434
[TBL] [Abstract][Full Text] [Related]
15. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
Serebruany VL; Pokov AN; Aradi D; Can M; DiNicolantonio J; Kipshidze N; Atar D
Am J Ther; 2014; 21(6):482-90. PubMed ID: 23698186
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
17. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
18. [Renin as a target of direct pharmacological block in arterial hypertension].
Mukhin NA; Fomin VV
Ter Arkh; 2009; 81(8):5-9. PubMed ID: 19799192
[TBL] [Abstract][Full Text] [Related]
19. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
20. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS).
Volman S; Benitez FN; Cedenio H; Giorgi M; Jaramillo N; Molina N; Zilberman J
Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):189-96. PubMed ID: 23723254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
